Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Deena Rodney

Nurse Practitioner, Family Maitland, FL Nurse Practitioner

NPI 1932408028 CMS profile 10819339

301 N Maitland Ave, Maitland, FL 32751

Open in the dashboard

General payments

$322,542

1,790 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Deena Rodney of Maitland, FL is reported in the CMS Open Payments database as having received $322,542 across 1,790 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $97,877 478
2024 General $64,272 389
2023 General $49,561 317
2022 General $71,034 347
2021 General $39,798 259

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Deena Rodney
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Deena Rodney were reported at $97,877. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Deena Rodney Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $39,798 $124 $35–$379 $132
2022 $71,034 $141 $44–$430 $149
2023 $49,561 $154 $49–$476 $160
2024 $64,272 $165 $51–$504 $164
2025 $97,877 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Alexion Pharmaceuticals, Inc. $176,781 448 payments
  2. UCB, Inc. $34,496 82 payments
  3. Janssen Biotech, Inc. $28,007 54 payments
  4. Allergan Inc. $21,236 30 payments
  5. AbbVie, Inc. $20,101 198 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $10,960 41 payments
  7. Amgen Inc. $10,819 49 payments
  8. Argenx US, Inc. $4,236 85 payments
  9. Neurocrine Biosciences, Inc. $2,145 112 payments
  10. Biogen, Inc. $1,498 66 payments
  11. Other $12,264 625 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $188,366 153 payments
  2. Travel and Lodging $60,405 228 payments
  3. Consulting Fee $36,821 24 payments
  4. Food and Beverage $36,633 1,373 payments
  5. Education $316 12 payments
Products named General payments · program years 2021–2025
  1. ULTOMIRIS $122,384 322 payments
  2. BOTOX Neuroscience $35,227 55 payments
  3. Rystiggo $11,608 21 payments
  4. HYQVIA $10,908 39 payments
  5. SOLIRIS Rare Disease $10,245 26 payments
  6. Soliris Immunology $8,175 32 payments
  7. Zilbrysq Neurology $7,105 16 payments
  8. Zilbrysq Neurology $4,950 6 payments
  9. UPLIZNA $3,689 30 payments
  10. BOTOX Botox Therapeutic $2,400 20 payments
  11. Other $23,588 1,221 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

39

Median for Nurse Practitioner: 389

Drug cost

$1,619

Median for Nurse Practitioner: $21,885

Branded share of claims

30.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rivastigmine Rivastigmine Tartrate Brand 12 $762
Memantine Hcl Generic 13 $730
Buspirone Hcl Generic 14 $127

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 48 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ULTOMIRIS
$26,650 — —
HYQVIA
$9,447 — —
BOTOX
$5,900 — —
Rystiggo
$3,897 — —
Zilbrysq
$1,198 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 48 with Patron

Records

1,790 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record